Skip to content
Screener

ARS Pharmaceuticals, Inc. SPRY Price / earnings

Price / earnings at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
35.1×-720×
Viatris logo
ViatrisVTRS
6.5×-6.4×
AMP
Amphastar PharmaceuticalsAMPH
11.3×+2.7×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
105.5×—

Other financials

Income statement

See full
Revenue$22.7M+184%
Operating income-$60.1M-61.8%
Net income-$60.6M-78.6%
EPS (diluted)-$0.61-74.3%

Balance sheet

See full
Cash & equivalents$24.3M-39.0%
Total debt$96.5M+132,122%
Total equity$61.3M-73.2%
Total assets$287.6M-12.1%

Cash flow

See full
Operating cash flow-$44.9M-10.3%
CapEx--100%
Free cash flow-$44.9M-10.1%

Valuation

See full
Market cap$611.71M-62.0%
Enterprise value$683.91M-56.1%
P/S6.2×-8.1×

Profitability

See full
Operating margin-204.5%—
Net margin-200%-219pp
FCF margin-177.1%-206pp

Returns & leverage

See full
Return on equity-136.4%-144pp
Debt / equity1.6×+1.6×
Current ratio4.9×-6.1×

Where this comes from

Calculated from ARS Pharmaceuticals, Inc.’s reported figures.

market cap/net income=128.2×

Based on the most recent quarter.

The source filing: ARS Pharmaceuticals, Inc.’s 10-K, filed March 9, 2026. Open the filing →

Filed
Mar 9, 2026, 6:07 AM EDT
Fiscal year
FY2025
Accession
0001193125-26-097478

FAQ

What is ARS Pharmaceuticals, Inc.'s price / earnings?
ARS Pharmaceuticals, Inc. (SPRY) reported price / earnings of 128.2× in Q4 2024.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about ARS Pharmaceuticals, Inc.'s price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude